Stock ZYME ZYMEWORKS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Zymeworks Inc.

Equities

ZYME

US98985Y1082

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
8.85 USD +2.08% Intraday chart for Zymeworks Inc. -2.64% -14.82%
Apr. 08 Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting CI
Apr. 04 Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer CI

Business Summary

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

Number of employees: 275

Sales per Business

USD in Million2022Weight2023Weight Delta
Multifunctional Biotherapeutics
100.0 %
412 100.0 % 76 100.0 % -81.57%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
412 100.0 % 76 100.0 % -81.57%

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 651,219 0 0 93.13 %
Stock B 1 70,568,222 66,327,779 ( 93.99 %) 0

Shareholders

NameEquities%Valuation
EcoR1 Capital, LLC
19.04 %
13,437,473 19.04 % 141 M $
EcoR1 Capital, LLC
19.04 %
13,437,473 19.04 % 141 M $
BVF, Inc.
8.318 %
5,870,000 8.318 % 62 M $
Redmile Group LLC
8.205 %
5,790,230 8.205 % 61 M $
Morgan Stanley Investment Management, Inc.
6.889 %
4,861,286 6.889 % 51 M $
BlackRock Advisors LLC
4.995 %
3,524,735 4.995 % 37 M $
Rubric Capital Management LP
4.925 %
3,475,384 4.925 % 37 M $
Daniel Cookson
3.949 %
2,786,936 3.949 % 29 M $
Vanguard Fiduciary Trust Co.
3.393 %
2,394,712 3.393 % 25 M $
Credit Suisse Funds AG
3.264 %
2,303,621 3.264 % 24 M $

Company contact information

Zymeworks, Inc.

108 Patriot Drive Suite A

19709, Middletown

+(302) 274-8744

http://www.zymeworks.com
address Zymeworks Inc.(ZYME)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Zymeworks Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.67 USD
Average target price
14.17 USD
Spread / Average Target
+63.40%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ZYMEWORKS INC. Stock Zymeworks Inc.
-14.82% 612M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.10% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.11% 96.07B
ARGENX SE Stock argenx SE
-1.80% 21.66B
BIONTECH SE Stock BioNTech SE
-17.75% 20.77B
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.19% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.18% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.90% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ZYME Stock
  4. Company Zymeworks Inc.